Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Merck's interest expense for the
three
months ended in Dec. 2023 was $ -310 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-1,146 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Merck's Operating Income for the
three
months ended in Dec. 2023 was $ -1,713 Mil. Merck's Interest Expense for the
three
months ended in Dec. 2023 was $ -310 Mil.
Merck did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Merck Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,146 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck (NYSE:MRK) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Merck's Interest Expense for the
three
months ended in Dec. 2023 was $-310 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-1,713 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $33,683 Mil.
Merck's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| Merck did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Merck (MRK) Business Description
Traded in Other Exchanges
Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Executives
| Johannes Jacobus Oosthuizen |
officer: SVP, U.S. Market |
2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
| Richard R. Deluca |
officer: EVP&Pres, Merck Animal Heallth |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Steven Mizell |
officer: EVP,Human Resources |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Joseph Romanelli |
officer: President, Human Health Int?l |
126 EAST LINCOLN AVENUE, RAHWAY NJ 07065 |
| Rita A Karachun |
officer: Sr. VP Fince-Global Controller |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Jennifer Zachary |
officer: EVP, General Counsel |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| David Michael Williams |
officer: EVP,Chief Info&Digital Officer |
MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Robert M Davis |
officer: Evp, Global Svcs & CFO |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Sanat Chattopadhyay |
officer: Exe V-P & Pres. MMD |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Kenneth C Frazier |
officer: Chairman, President & CEO |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Chirfi Guindo |
officer: Chief Marketing Officer |
C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
| Baker Douglas M Jr |
director |
370 WBASHA ST NORTH, ST PAUL MN 55102 |
| Arpa Garay |
officer: SVP Human Health Global Mktg. |
2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
| Caroline Litchfield |
officer: EVP & CFO |
2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
| Julie L. Gerberding |
officer: EVP Strat Comm, GI Pub Policy |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRK has been successfully added to your 